文献速递血栓与止血

内源性抗菌肽LL37通过甲酰肽受体2(FPR2/ALX)诱导血小板活化并促进血栓形成

The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation.
PubMed 文献 · Blood Adv · 2018-01-01

研究发现血小板表达甲酰肽受体2(FPR2/ALX),其配体LL37可激活多种血小板功能、增强小鼠血栓形成并缩短尾出血时间。利用药理学抑制剂及Fpr2/3缺陷小鼠证实LL37的功能依赖于FPR2/ALX。鉴于多种炎症性疾病中LL37水平升高,结果提示LL37与FPR2/ALX在血小板相关并发症中起关键作用。

要点

  • 血小板表达FPR2/ALX,LL37通过该受体激活血小板功能。
  • LL37增强小鼠血栓形成并缩短尾出血时间。
  • 药理学抑制或Fpr2/3缺陷可阻断LL37对血小板的功能依赖。

核心结论

  • LL37通过血小板上FPR2/ALX激活血小板功能、增强血栓形成并缩短小鼠尾出血时间,提示LL37与FPR2/ALX在炎症性疾病相关血小板并发症中起关键作用。

研究设计与样本

  • 基础研究:在血小板中发现FPR2/ALX,并通过药理学抑制剂及Fpr2/3(人FPR2/ALX的同源物)缺陷小鼠确定LL37的功能依赖性。

主要发现

  • LL37激活一系列血小板功能并增强血栓形成。
  • LL37缩短小鼠尾出血时间。
  • 利用药理学抑制剂和Fpr2/3缺陷小鼠证实LL37的功能依赖于FPR2/ALX。
  • 多种炎症性疾病中LL37水平升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platelet-associated complications including thrombosis, thrombocytopenia, and hemorrhage are commonly observed during various inflammatory diseases such as sepsis, inflammatory bowel disease, and psoriasis. Despite the reported evidence on numerous mechanisms/molecules that may contribute to the dysfunction of platelets, the primary mechanisms that underpin platelet-associated complications during inflammatory diseases are not fully established. Here, we report the discovery of formyl peptide receptor 2, FPR2/ALX, in platelets and its primary role in the development of platelet-associated complications via ligation with its ligand, LL37. LL37 acts as a powerful endogenous antimicrobial peptide, but it also regulates innate immune responses. We demonstrate the impact of LL37 in the modulation of platelet reactivity, hemostasis, and thrombosis. LL37 activates a range of platelet functions, enhances thrombus formation, and shortens the tail bleeding time in mice. By utilizing a pharmacological inhibitor and Fpr2/3 (an ortholog of human FPR2/ALX)-deficient mice, the functional dependence of LL37 on FPR2/ALX was determined. Because the level of LL37 is increased in numerous inflammatory diseases, these results point toward a critical role for LL37 and FPR2/ALX in the development of platelet-related complications in such diseases. Hence, a better understanding of the clinical relevance of LL37 and FPR2/ALX in diverse pathophysiological settings will pave the way for the development of improved therapeutic strategies for a range of thromboinflammatory diseases.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Salamah MF, Ravishankar D, Kodji X, et al. The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation. Blood Adv. 2018. PMID: 30413433. doi:10.1182/bloodadvances.2018021758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。